$1.06
-0.01 (-0.93%)
Open$1.08
Previous Close$1.07
Day High$1.08
Day Low$1.04
52W High$5.48
52W Low$0.88
Volume—
Avg Volume80.7K
Market Cap27.48M
P/E Ratio—
EPS$-0.26
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,230.2% upside
Current
$1.06
$1.06
Target
$24.70
$24.70
$17.28
$24.70 avg
$43.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.17M | 1.04M | 9.21M |
| Net Income | -11,243,139 | -9,012,134 | 1.19M |
| Profit Margin | -962.1% | -914.0% | 12.9% |
| EBITDA | -9,709,254 | -8,214,990 | 1.73M |
| Free Cash Flow | — | — | 900.3K |
| Rev Growth | +12.3% | +12.3% | -0.3% |
| Debt/Equity | 1.46 | 1.46 | 0.87 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |